Home / BCDA : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does BCDA make money? Does BCDA have pricing power? What's the Earnings Whisper? Will BCDA profit more as the business scales? What is BCDA's management track record? Is BCDA's current price justified?

BioCardia, Inc.

$1.08 -$0.19 (-14.96%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$1.1

Day Range

$1.08$1.14

Year Range

$0.75$2.21

Market Cap

16.08M

AVG Volume

3.15M

Trailing/Forward PE

-1.42/-

PEG ratio

0.08

Dividend Yield

Next Earnings Date

2026-11-11

Primary Exchange

NASDAQ

Revenue (USD)

BCDA Revenue (USD) by year
Period	Revenue (USD)
2025	0
2024	58K
2023	477K
2022	1.35M
2021	1.01M
2020	145K
2019	711K
2018	625K
2017	479K
2016	-4.87M

Net Income (USD)

BCDA Net Income (USD) by year
Period	Net Income (USD)
2025	-8.23M
2024	-7.95M
2023	-11.57M
2022	-11.91M
2021	-12.62M
2020	-15M
2019	-14.71M
2018	-13.99M
2017	-12.31M
2016	-10.31M

Operating Income (USD)

BCDA Operating Income (USD) by year
Period	Operating Income (USD)
2025	-8.28M
2024	-8M
2023	-11.64M
2022	-11.9M
2021	-12.63M
2020	-15.53M
2019	-14.21M
2018	-14.1M
2017	-12.4M
2016	-7.67M

EBITDA (USD)

BCDA EBITDA (USD) by year
Period	EBITDA (USD)
2025	-7.92M
2024	-7.79M
2023	-11.49M
2022	-11.75M
2021	-12.56M
2020	-15.33M
2019	-14.4M
2018	-13.87M
2017	-12.39M
2016	-7.61M

Cash Flows (USD)

BCDA Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-7.44M
2024	-8.03M
2023	-9.99M
2022	-10.63M
2021	-10.48M
2020	-12.39M
2019	-9.59M
2018	-11.13M
2017	-8.81M
2016	-5.52M

EPS (USD)

BCDA EPS (USD) by year
Period	EPS (USD)
2025	-1.81
2024	-3.34
2023	-8.24
2022	-9.99
2021	-11.21
2020	-24.82
2019	-41.57
2018	-49.19
2017	-44.15
2016	-298.91

Expenses (USD)

BCDA Expenses (USD) by year
Period	Expenses (USD)
2025	6.11M
2024	5.11M
2023	7.74M
2022	9.73M
2021	9.92M
2020	11.56M
2019	14.56M
2018	14.28M
2017	12.33M
2016	7.44M

Cash & Debt (USD)

BCDA Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	2.5M
2024	2.37M
2023	1.1M
2022	7.36M
2021	12.87M
2020	21.41M
2019	5.58M
2018	5.36M
2017	12.69M
2016	21.35M

Debt ratios

BCDA Debt ratios by year
Period	Debt ratios
2025	0.05
2024	0.03
2023	-0
2022	0.11
2021	0.2
2020	0.37
2019	0.09
2018	0.16

Margins

BCDA Margins by year
Period	Margins
2024	-6044.83%
2023	-1519.71%
2022	-397.86%
2021	-552.22%
2020	-4842.76%
2019	28.83%
2018	17.28%
2017	-44.05%
2016	48.71%
2015	-398.84%

Return on Capital

BCDA Return on Capital by year
Period	Return on Capital
2025	-919.33%
2024	-949.34%
2023	721.83%
2022	-243.4%
2021	-121.67%
2020	-78.24%
2019	-620.59%
2018	-368.86%
2017	-110.63%
2016	-50.09%

Shares Outstanding

BCDA Shares Outstanding by year
Period	Shares Outstanding
2025	10.76M
2024	2.74M
2023	1.5M
2022	1.22M
2021	1.14M
2020	886.43K
2019	455.01K
2018	287.01K
2017	283.09K
2016	36.84K

Book Value Per Share (USD)

BCDA Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	0.08
2024	0.31
2023	-1.07
2022	4.01
2021	9.12
2020	21.63
2019	5.21
2018	13.21
2017	39.3
2016	558.61

Total Assets (USD)

BCDA Total Assets (USD) by year
Period	Total Assets (USD)
2025	3.41M
2024	3.72M
2023	2.99M
2022	9.79M
2021	15.72M
2020	23.42M
2019	7.68M
2018	6.42M
2017	13.54M
2016	22.08M

Employee Count

BCDA Employee Count by year
Period	Employee Count
2025	17
2024	17
2023	16
2022	30
2021	28
2020	24
2019	20
2018	27
2017	24
2016	14

PE Ratio

BCDA PE Ratio by year
Period	PE Ratio
Mar 17	19.25
Mar 17	19.15
Mar 17	21.56
Mar 17	23.49
Feb 17	22.69
Feb 17	29.26
Feb 17	30.03
Feb 17	29.84
Jan 17	31.92
Jan 17	34.27
Jan 17	35.32
Jan 17	37.96
Dec 16	41.58
Dec 16	28.03
Dec 16	16.17
Dec 16	13.52
Dec 16	13.16
Nov 16	13.97
Nov 16	6.74
Nov 16	5.96
Nov 16	6.12
Oct 16	5.47
Oct 16	4.24

Free Cash Flow Yield

BCDA Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-57.98%
Sep 26	-57.98%
Aug 26	-54.45%
Aug 26	-61.99%
Aug 26	-64.3%
Aug 26	-70.78%
Jul 26	-84.01%
Jul 26	-81.45%
Jul 26	-83.85%
Jul 26	-75.69%
Jul 26	-57.7%
Jun 26	-57.7%
Jun 26	-71.58%
Jun 26	-78.69%
Jun 26	-67.23%
May 26	-74.46%
May 26	-72.51%
May 26	-68.56%
May 26	-62.34%
May 26	-62.34%
Apr 26	-59.66%
Apr 26	-58.64%
Apr 26	-58.64%
Apr 26	-57.67%
Mar 26	-59.66%
Mar 26	-99.74%
Mar 26	-94.99%
Mar 26	-101.43%
Feb 26	-92.78%
Feb 26	-105.92%
Feb 26	-104.99%
Feb 26	-95.75%
Jan 26	-97.31%
Jan 26	-89.32%
Jan 26	-85.49%
Jan 26	-84.89%
Jan 26	-94.24%
Dec 25	-94.24%
Dec 25	-94.24%
Dec 25	-82.55%
Dec 25	-87.37%
Nov 25	-82.55%
Nov 25	-87.37%
Nov 25	-97.31%
Nov 25	-128.54%
Oct 25	-119.36%
Oct 25	-120.22%
Oct 25	-115.24%
Oct 25	-124.7%
Oct 25	-122.87%
Sep 25	-117.68%
Sep 25	-144.05%
Sep 25	-78.09%
Sep 25	-81.12%
Aug 25	-84.4%
Aug 25	-87.49%
Aug 25	-87.03%
Aug 25	-165.32%
Aug 25	-138.93%
Jul 25	-125.92%
Jul 25	-132.7%
Jul 25	-123.82%
Jul 25	-139.58%
Jun 25	-137.64%
Jun 25	-142.27%
Jun 25	-135.74%
Jun 25	-136.37%
May 25	-137%
May 25	-150.21%
May 25	-121.28%
May 25	-102.71%
May 25	-109.22%
Apr 25	-148.58%
Apr 25	-152.45%
Apr 25	-147.83%
Apr 25	-145.63%
Mar 25	-104.54%
Mar 25	-97.2%
Mar 25	-99.44%
Mar 25	-98.68%
Feb 25	-128.63%
Feb 25	-111.92%
Feb 25	-91.04%
Feb 25	-109.09%
Jan 25	-104.67%
Jan 25	-118.06%
Jan 25	-118.6%
Jan 25	-121.38%
Jan 25	-111.92%
Dec 24	-105.1%
Dec 24	-131.24%
Dec 24	-124.3%
Dec 24	-121.95%
Nov 24	-113.4%
Nov 24	-114.4%
Nov 24	-139.75%
Nov 24	-167.56%
Nov 24	-158.45%
Oct 24	-156.48%
Oct 24	-140.78%

Price to Sales

BCDA Price to Sales by year
Period	Price to Sales
Aug 25	1637.25
Aug 25	1948.24
Jul 25	2149.47
Jul 25	2039.71
Jul 25	2186.05
Jul 25	1939.09
Jun 25	1966.53
Jun 25	1902.51
Jun 25	1993.97
Jun 25	1984.83
May 25	1975.68
May 25	1801.89
May 25	2231.79
May 25	134.83
May 25	126.79
Apr 25	93.2
Apr 25	90.84
Apr 25	93.67
Apr 25	95.09
Mar 25	132.47
Mar 25	105.91
Mar 25	103.52
Mar 25	104.32
Feb 25	80.03
Feb 25	91.98
Feb 25	113.08
Feb 25	94.37
Jan 25	98.35
Jan 25	87.2
Jan 25	86.8
Jan 25	84.81
Jan 25	91.98
Dec 24	97.95
Dec 24	78.44
Dec 24	82.82
Dec 24	84.41
Nov 24	90.78
Nov 24	89.99
Nov 24	73.66
Nov 24	9.91
Nov 24	10.48
Oct 24	10.61
Oct 24	11.8
Oct 24	11.62
Oct 24	12.02
Sep 24	12.89
Sep 24	11.14
Sep 24	13.02
Sep 24	9.96
Aug 24	13.38
Aug 24	10.92
Aug 24	14.56
Aug 24	9.6
Aug 24	10.74
Jul 24	10.71
Jul 24	10.42
Jul 24	11.64
Jul 24	10.64
Jun 24	10.64
Jun 24	10.74
Jun 24	12.21
Jun 24	13.32
May 24	16.55
May 24	18.59
May 24	21.06
May 24	18.7
May 24	17.95
Apr 24	17.79
Apr 24	17
Apr 24	18.42
Apr 24	18.2
Mar 24	19.24
Mar 24	15.52
Mar 24	14.79
Mar 24	15.98
Mar 24	21.99
Feb 24	17.04
Feb 24	17.04
Feb 24	15.55
Feb 24	16.18
Jan 24	17.39
Jan 24	16.58
Jan 24	24.6
Jan 24	24.62
Dec 23	25.18
Dec 23	24.65
Dec 23	22.8
Dec 23	23.86
Dec 23	25.48
Nov 23	26.9
Nov 23	27.33
Nov 23	44.37
Nov 23	57.56
Oct 23	54.58
Oct 23	56.02
Oct 23	63.31
Oct 23	57.56
Sep 23	61.87
Sep 23	58.42
Sep 23	56.89

EV/EBITDA

BCDA EV/EBITDA by year
Period	EV/EBITDA
Mar 17	16.93
Mar 17	16.83
Mar 17	19.24
Mar 17	21.16
Feb 17	20.37
Feb 17	26.94
Feb 17	27.71
Feb 17	27.52
Jan 17	29.6
Jan 17	31.95
Jan 17	33.01
Jan 17	35.65
Dec 16	39.27
Dec 16	25.71
Dec 16	13.85
Dec 16	11.19
Dec 16	10.83
Nov 16	11.65
Nov 16	4.41
Nov 16	3.63
Nov 16	3.79
Oct 16	3.14
Oct 16	1.9

Price/Operating Cashflow

BCDA Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Mar 17	18.09
Mar 17	18
Mar 17	20.27
Mar 17	22.07
Feb 17	21.33
Feb 17	27.5
Feb 17	28.23
Feb 17	28.05
Jan 17	30
Jan 17	32.21
Jan 17	33.2
Jan 17	35.68
Dec 16	39.08
Dec 16	26.35
Dec 16	15.2
Dec 16	12.71
Dec 16	12.37
Nov 16	13.13
Nov 16	6.33
Nov 16	5.61
Nov 16	5.75
Oct 16	5.14
Oct 16	3.98

Price to Book

BCDA Price to Book by year
Period	Price to Book
Sep 26	4.84
Sep 26	4.84
Aug 26	5.15
Aug 26	4.52
Aug 26	4.36
May 26	13.34
May 26	13.34
Apr 26	13.94
Apr 26	14.18
Apr 26	14.18
Apr 26	14.42
Mar 26	13.94
Mar 26	2.87
Mar 26	3.01
Mar 26	2.82
Feb 26	3.08
Feb 26	2.7
Feb 26	2.72
Feb 26	2.99
Jan 26	2.94
Jan 26	3.2
Jan 26	3.35
Jan 26	3.37
Jan 26	3.03
Dec 25	3.03
Dec 25	3.03
Dec 25	3.47
Dec 25	3.27
Nov 25	3.47
Nov 25	3.27
Nov 25	2.94
May 25	9.34
May 25	8.79
Apr 25	6.46
Apr 25	6.29
Apr 25	6.49
Apr 25	6.59
Mar 25	9.18
Mar 25	2.73
Mar 25	2.67
Mar 25	2.69
Feb 25	2.06
Feb 25	2.37
Feb 25	2.92
Feb 25	2.43
Jan 25	2.54
Jan 25	2.25
Jan 25	2.24
Jan 25	2.19
Jan 25	2.37
Dec 24	2.53
Dec 24	2.02
Dec 24	2.14
Dec 24	2.18
Nov 24	2.34
Nov 24	2.32
Nov 24	1.9
Nov 23	14.96
Oct 23	14.19
Oct 23	14.56
Oct 23	16.46
Oct 23	14.96
Sep 23	16.08
Sep 23	15.19
Sep 23	14.79
Sep 23	17.21
Sep 23	29.12
Aug 23	31.24
Aug 23	32.22
Aug 23	33.21
Aug 23	29.63
Jul 23	31.09
Jul 23	63.07
Jul 23	74.22
Jul 23	88.88
Jun 23	85.05
Jun 23	82.19
Jun 23	74.54
Jun 23	67.53
Jun 23	60.21
May 23	59.25
May 23	53.2
May 23	61.48
May 23	22.46
Apr 23	23.14
Apr 23	22.58
Apr 23	22.01
Apr 23	22.46
Mar 23	21.9
Mar 23	26.93
Mar 23	25.49
Mar 23	26.79
Mar 23	29.41
Feb 23	28.36
Feb 23	31.11
Feb 23	29.15
Feb 23	31.11
Jan 23	31.63
Jan 23	30.72
Jan 23	29.93

No video analysis for this stock yet. Request one from our team.

News: BCDA

globenewswire.com · 10 Sep 2026

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.

globenewswire.com · 24 Aug 2026

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix).

seekingalpha.com · 13 Aug 2026

BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript

globenewswire.com · 5 Aug 2026

BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session.

zacks.com · 28 Jul 2026

New Strong Sell Stocks for July 28th

LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.

zacks.com · 14 Jul 2026

New Strong Sell Stocks for July 14th

AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.

globenewswire.com · 18 Jun 2026

BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the Company's Chief Executive Officer, Peter Altman, issued the following letter to shareholders.